Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.13
Bid: 2.01
Ask: 2.15
Change: 0.00 (0.00%)
Spread: 0.14 (6.965%)
Open: 2.13
High: 0.00
Low: 0.00
Prev. Close: 2.13
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sch 1 Update - ImmuPharma plc

24 Jan 2006 16:30

AIM24 January 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:ImmuPharma plc (currently named General Industries plc) COMPANY ADDRESS:50 Broadway, London COMPANY POSTCODE:SW1H 0BL COUNTRY OF INCORPORATION:England & Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Bio-pharmaceutical research and drug development DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):Up to 70,950,000 ordinary shares of 10 pence each (none held as treasury shares) CAPITAL TO BE RAISED ON ADMISSION:Up to £3.4 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Richard Leonard WARR (Executive Chairman)Dimitri DIMITRIOU (Chief Executive Officer)Dr Robert ZIMMER (Chief Scientific Officer)Douglas Gordon James PATERSON (Senior non-executive)Anthony Michael JOHNSON (Non-executive) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: After AdmissionDr Robert Zimmer* 34%Richard Warr* 21%Dimitri Dimitriou* 21% None of the above held any Shares prior to Admission *includes shares held by wife and/or family trusts NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:31 December EXPECTED ADMISSION DATE:17 February 2006 NAME AND ADDRESS OF NOMINATED ADVISER:Dawnay, Day Corporate Finance Limited, 17 Grosvenor Gardens, London SW1W 0BD NAME AND ADDRESS OF BROKER:KBC Peel Hunt Ltd, 111 Old Broad Street, London EC2N 1PH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the Admission Document will be available (during normal business hours) from Dawnay, Day CorporateFinance Limited, 17 Grosvenor Gardens, London SW1W 0BD and from KBC Peel Hunt, 111 Old Broad Street, London EC2N1PH until 17 March 2006 DATE OF NOTIFICATION:23 January 2006 NEW/ UPDATE (see note):Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th May 20167:00 amRNSFinal Results
26th Apr 20167:00 amRNSNotice of Results
22nd Apr 20169:50 amRNSHolding(s) in Company
9th Mar 20167:00 amRNSFirst European Site Opens - Patient Recruitment
8th Mar 201611:10 amRNSHolding(s) in Company
7th Mar 20163:31 pmRNSHolding(s) in Company
1st Mar 20167:00 amRNSEIS and VCT Qualifying Status and Issue of Equity
29th Feb 20168:02 amRNSHolding(s) in Company
24th Feb 201612:35 pmRNSIssue of Equity
22nd Feb 20161:39 pmRNSResult of GM
15th Feb 20167:00 amRNSUS PATIENTS COMMENCE DOSING IN PHASE III STUDY
5th Feb 201612:22 pmRNSPlacing and Subscription Raises £8.3 million
5th Feb 20167:00 amRNSProposed Placing and Subscription
21st Jan 20165:33 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSImmuPharma & Simbec-Orion - Investigators Meeting
7th Dec 20157:00 amRNSUpdate on the progress of Lupuzor
30th Nov 201511:55 amRNSHolding(s) in Company
4th Nov 20158:26 amRNSLupuzor Phase III Pivotal Trial Update
4th Nov 20157:00 amRNSLupuzor Phase III Pivotal Trial Update
23rd Oct 20157:00 amRNSDirectorate Change
30th Sep 20157:05 amRNSDirectorate Change
30th Sep 20157:00 amRNSInterim Results
29th Jul 20157:00 amRNSRichard Warr
27th Jul 20157:00 amRNSTERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25th Jun 20157:00 amRNSLupuzor's Founder Dr Slyviane Muller Awarded Medal
29th May 201512:50 pmRNSResult of AGM
6th May 20153:44 pmRNSAnnual Report & Accounts
6th May 20157:02 amRNSInterim Board Change
30th Apr 20157:05 amRNSDirectorate Change
30th Apr 20157:00 amRNSPreliminary Results
11th Feb 201512:02 pmRNSCANCER UPDATE: IPP-204106
27th Jan 20157:00 amRNSEnterprise Investment Scheme Status
22nd Jan 20157:00 amRNSCollaboration Agreement with Simbec-Orion
30th Oct 201411:10 amRNSHolding(s) in Company
28th Oct 20147:00 amRNSHolding(s) in Company
21st Oct 20147:00 amRNSAdditional Listing - Conditional Placing
20th Oct 20147:00 amRNSImmuPharma awarded EUR400,000 Grant
30th Sep 20147:05 amRNSHalf Yearly Report
30th Sep 20147:00 amRNSLupuzorT Gears Up To Start Pivotal Phase III trial
27th Jun 20141:11 pmRNSResult of AGM
27th Jun 20147:00 amRNSAccess to pioneering research in Bordeaux France
16th Jun 20147:00 amRNSNEW NUCANT PATENTS
23rd May 20147:00 amRNSAnnual Financial Report
21st May 20147:00 amRNSPreliminary Results
6th May 201412:47 pmRNSDr. Sylviane Muller - Presentation Abstract
23rd Apr 20147:00 amRNSDr. S Muller, founder of Lupuzor presentation.
11th Apr 20147:00 amRNSImmuPharma Sponsors the 2014 European Lupus Confer
14th Oct 20137:00 amRNSAdditional Listing
27th Sep 20137:00 amRNSHalf Yearly Report
13th Aug 20137:00 amRNSUPDATE CANCER PROGRAMME IPP-204106

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.